October 14, 2019     81.0F   27.2C   
Site Map | askUM | UM Home     
Miller School of Medicine at the University of Miami


News >>

<< previous article article listing next article >>

Dr. Jerry Goodwin Named to New Position at Sylvester


Pascal J. Goldschmidt, M.D., Senior Vice President for Medical Affairs and Dean of the Miller School of Medicine, has appointed W. Jarrard Goodwin, M.D., Chief Medical Officer of the Sylvester Comprehensive Cancer Center and the University of Miami Hospital and Clinics.

“Looking back at what Jerry Goodwin has accomplished over the past 14 years as director of Sylvester, it is nothing short of heroic,” said Dean Goldschmidt. “Step by step, Jerry was able to build a successful business model for the clinical affairs of the Center, and recruit, either directly or through collaborations, an army of cancer faculty, scientists, educators and physicians, who have metamorphosed the quality of the academic production and clinical delivery at Sylvester to make it a top-tier organization.

“We will always be grateful to Jerry for what he has done for us and our patients, and I am looking forward to working closely with him in his new role as Chief Medical Officer for Sylvester and the University of Miami Hospital and Clinics.”
Dr. Goodwin will also focus on building and optimizing Sylvester’s satellite locations in Deerfield Beach and Kendall.

“It has been a great privilege to lead Sylvester’s research program, and I am very proud of what we have accomplished together,” said Dr. Goodwin. “Now I am really looking forward to focusing more of my time and energy on the development of the hospital and clinics.”
Dr. Joseph Rosenblatt will serve as Interim Director of Sylvester while a national search for a new Director takes place. Dr. Rosenblatt will focus on continuing to strengthen the center’s research activities. Dr. Marc Lippman will take on the role of Deputy Director for Sylvester.
The changes take advantage of the academic leaders’ strengths and will move the Sylvester cancer center to an even stronger position to compete successfully for a National Cancer Institute core grant when the application is submitted next year.

“We will continue to develop and expand the outstanding clinical and research programs developed during Dr. Jerry Goodwin’s tenure as Director,” said Dr. Rosenblatt. “We will work together with hospital and University leadership, cancer center faculty and our exceptional community supporters to strengthen the center scientifically and build upon Dr. Goodwin’s extraordinary legacy.”